Gingivitis (Mouth and Dental Disorders) - Drugs in Development, 2021

October 2021 | 37 pages | ID: G5457C0AE5D3EN
Global Markets Direct

Abstracts

Gingivitis (Mouth and Dental Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis - Drugs In Development, 2021, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gingivitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gingivitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gingivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Gingivitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gingivitis (Mouth And Dental Disorders).
• The pipeline guide reviews pipeline therapeutics for Gingivitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gingivitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gingivitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gingivitis (Mouth And Dental Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gingivitis (Mouth And Dental Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gingivitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Gingivitis - Overview
Gingivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gingivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gingivitis - Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Avicanna Inc
Pacgen Life Science Corp
Gingivitis - Drug Profiles
AMY-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLXA-4ME - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KSL-W - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB1 and CB2 for Gingivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gingivitis - Dormant Projects
Gingivitis - Product Development Milestones
Featured News & Press Releases
Mar 09, 2021: Amyndas announces positive top-line phase 2 results for investigational AMY-101 in adults with periodontal inflammation and gingivitis
Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
Jan 24, 2017: Pacgen announces new markets for P113 products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Gingivitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Gingivitis - Pipeline by Amyndas Pharmaceuticals LLC, 2021
Gingivitis - Pipeline by Avicanna Inc, 2021
Gingivitis - Pipeline by Pacgen Life Science Corp, 2021
Gingivitis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gingivitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021